GlassScriptPhysician profile
Cybil R Corning
NPI 1235337304
$2,986.61
in general payments reported to CMS, 2019-2025
28 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $685 · 2021: $83.34 · 2022: $190 · 2023: $272 · 2024: $364 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,378.22 | 2019-2024 | |
| Amgen INC. | $284.95 | 2019-2023 | Lumakras |
| Coloplast Corp | $263.67 | 2019-2025 | Sensura Mio |
| Incyte Corporation | $172.48 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Sobi, INC | $84.90 | 2024-2025 | |
| Medtronic, INC. | $81.35 | 2022-2023 | Signia |
| Bayer Healthcare Pharmaceuticals INC. | $81.12 | 2019-2023 | |
| Davol INC. | $62.72 | 2020 | |
| Myovant Sciences INC. | $54.91 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $46.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $38.44 | 2021-2025 | Lynparza, Keytruda |
| Seagen INC. | $38.31 | 2023 | Tukysa, Adcetris |
| Pfizer INC. | $35.39 | 2024-2025 | |
| Genentech USA, INC. | $34.89 | 2025 | Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $32.58 | 2024 | Fruzaqla, Alunbrig |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $31.55 | 2023 | Exparel |
| Blueprint Medicines Corporation | $28.65 | 2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $28.38 | 2025 | |
| Beone Medicines USA, INC. | $28.10 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $27.61 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Orgovyx |
| Exelixis INC. | $22.78 | 2025 | Cabometyx |
| Genzyme Corporation | $21.74 | 2025 | |
| Biom'Up Sa | $20.40 | 2019 | |
| Baxter Healthcare | $16.80 | 2024 | Tisseel |
| Solventum Corporation | $16.27 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C. Dermatac |
| Lilly USA, LLC | $14.45 | 2023 | Jaypirca |
| Axonics, INC. | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cybil Corning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.